Kymera Therapeutics, Inc. (KYMR) stock analysis
In our weekly check, Kymera Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 14.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as KYMR.
What our checks show for KYMR
Red flags
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The net margin fell by 204 points over 5 years, to -342%: the company keeps less of each sale as profit.
- Weak EPS forecast
- Analysts expect revenue to shrink about 34% a year.
- Analysts expect the net margin to shrink by 1147 points from today's -342%.
- Earnings per share grew only 8.1% a year over the last 3 years.
- The company is losing money: the net margin is -342%.
- Free cash flow is negative (-283% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 55.4% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 88% from a peak. Would you have held through that?
- Beta 2.03: the stock usually moves more than the market, both up and down.
- The share count grew by 44.6% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Recovering from its deepest fall took about 2.1 years.
Strengths
- Debt is low: 0.05x equity.
- The gross margin is 175% and has risen by 74.5 points: pricing power is holding.
- Revenue grew 29.7% a year over the last 3 years.
- A large company: market value $10.89 billion.
Similar companies
BMRN · SMMT · HALO · TECH · PCVX · MDGL
Questions
What grade does Kymera Therapeutics, Inc. (KYMR) have?
In our weekly check, Kymera Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 14. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of KYMR stock?
This week's biggest flags for Kymera Therapeutics, Inc.: Weak interest cover, Margins falling, Weak EPS forecast. In total 16 of 22 checks show a warning or a red flag.
What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as KYMR.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis